Anti-PM-Scl antibodies in a patient with inclusion body myositis [12]

Rheumatology

Volumn 42, Issue 8, 2003, Pages 1016-1018

  Selva O'Callaghan, A ^a,b   Mijares Boeckh Behrens, T ^a   Labrador Horrillos, M ^a   Solans Laque, R ^a   Grau Junyent, J Ma ^a   Vilardell Tarres, M ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; AUTOIMMUNITY; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; FEMALE; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; INCLUSION BODY MYOSITIS; LABORATORY TEST; LETTER; MUSCLE BIOPSY; MUSCLE STRENGTH; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AUTOANTIBODIES; EXORIBONUCLEASES; FEMALE; HUMANS; MUSCLES; MYOSITIS, INCLUSION BODY; NUCLEAR PROTEINS;

EID: 0141727718     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg253     Document Type: Letter

References (10)

1. Yunis J, Samaha F. Inclusion body myositis. Lab Invest 1971; 25:240-8.
2. Askanas V, Engel WK. New advances in inclusion body myositis. Curr Opin Rheumatol 1993;5:732-41.
3. Targoff IN. Update on myositis-specific and myositis associated autoantibodies. Curr Opin Rheumatol 2000;12:475-81.
4. Mikol J, Engel AG. Inclusion body myositis. In: Engel AG, Franzini-Armstrong C, eds. Myology, Vol. II. New York: McGraw Hill, 1994:1384-98.
5. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-7.
6. Hengstman GJ, van Engelen BG, Badrising UA, van den Hoogen FHJ, van Venrooij WJ. Presence of anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 1998;44:423.
7. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
8. Hengstman GJD, Ter Laak HJ, Van Engelen BGM, Van Venrooij WJ. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001;70:706.
9. Ioannou Y, Sultan S, Isenberg DA. Myositis overlap syndromes. Curr Opin Rheumatol 1999;11:468-74.
10. Jablonska S, Blaszczyk M. Scleromyositis: a scleroderma/polymyositis overlap syndrome. Clin Rheumatol 1998;17:525-32.